| Association between SARS-CoV-2 infection and anti-apolipoprotein A-1 antibody in children | Frontiers in immunology |  | | 2025 | 67 | 136 |
|
| Anti-Apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox inrheumatoid arthritis | ESC (Europan Society of Cardiology) Congress 2024 | | | 2024 | 13 | 0 |
|
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox in rheumatoid arthritis | 92nd EAS (European Atherosclerosis Society) Congress | | | 2024 | 22 | 0 |
|
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritis | Frontiers in cardiovascular medicine | | | 2024 | 128 | 282 |
|
| Linking antibody against apolipoprotein A-1 to nonalcoholic steatohepatitis in mice | 92nd EAS (European Atherosclerosis Society) Congress | | | 2024 | 17 | 0 |
|
| Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associatedsteatohepatitis in mice | ESC (Europan Society of Cardiology) Congress 2024 | | | 2024 | 15 | 0 |
|
| Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice | International journal of molecular sciences | | | 2024 | 136 | 184 |
|
| Antibody against apolipoprotein-A1, Metabolic-Associated Fatty Liver Diseaseand cardiovascular risk : a translational study | ESC (European Society of Cardiology) Congress 2023 | | | 2023 | 15 | 0 |
|
| Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study | Journal of translational medicine | | | 2023 | 152 | 186 |
|
| Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases | Frontiers in immunology | | | 2023 | 139 | 106 |
|
| Serum Level of Cytokeratin 18 (M65) as a Prognostic Marker of High Cardiovascular Disease Risk in Individuals with Non-Alcoholic Fatty Liver Disease | Biomolecules | | | 2023 | 83 | 240 |
|
| High antibody titers against apolipoprotein-A1 in NAFLD: a possible link between fatty liver disease and CVD? | 90th European Atherosclerosis Society (EAS) congress | | | 2022 | 170 | 0 |
|
| SARS-COV2- infection as a trigger of humoral response against apolipoprotein A-1 | EAS Congress 2021 | | | 2021 | 392 | 38 |
|
| SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1 | European Journal of Clinical Investigation | | | 2021 | 432 | 283 |
|
| Autoantibodies directed against apolipoprotein-A1 as a potential contributor to Non-Alcoholic Fatty Liver Disease | 89th Europen Society of Atherosclerosis (EAS) | | | 2021 | 153 | 0 |
|
| Auto-antibodies against apolipoprotein a-1 block cancer cells proliferation and induce apoptosis | Oncotarget | | | 2020 | 185 | 147 |
|
| Activation of human B cells negatively regulates TGF-β1 production | Journal of Neuroinflammation | | | 2017 | 603 | 336 |
|
| The neurotrophic hepatocyte growth factor induces protolerogenic human dendritic cells | Journal of neuroimmunology |  | | 2014 | 562 | 0 |
|
| Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients | PloS one | | | 2012 | 703 | 291 |
|
